TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06687733: A Phase I/II Study for the Safety and Efficacy of Intravenous Infusion With NGGT002 in Adults Patients With Phenylketonuria

Sponsor: NGGT (Suzhou) Biotechnology Co., Ltd. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,853,840

Rescue Site Savings

+$3,217,080

Unlock Full NCT06687733 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06687733 Rescue Dossier →